Is the financing that IKT received officially confirmed or was it just an announcement? Will there be further follow up that would increase the price again via investor confidence?

The financing that Inhibikase Therapeutics (IKT) received has been officially confirmed through multiple announcements and disclosures. The company has disclosed the pricing of a private placement financing valued at approximately $110 million, which is set to close on October 21, 2024. This financing round has been led by new investor Soleus Capital and includes participation from a consortium of new investors, indicating a strong investor interest and confidence in the company's future prospects.

The financing is intended to propel the initiation of a Phase 2b trial in pulmonary arterial hypertension (PAH) and support general corporate functions. The transaction is expected to close on October 21, 2024, with Jefferies acting as the lead placement agent and Maxim Group LLC as a co-placement agent.

The announcement of this financing has already led to a significant increase in IKT's stock price, with the company's shares trading higher by 31.1% to $1.56 on the day of the announcement. This price increase reflects investor confidence in the company's future prospects, as the financing is intended to support a Phase 2b trial for PAH, which is a significant milestone in the company's development pipeline.

The closing of the financing and the subsequent use of proceeds to advance the company's lead program, IkT-001Pro, into a late-stage trial in PAH are expected to provide further validation of IKT's technology and pipeline, which could lead to increased investor confidence and potentially higher stock prices.

In conclusion, the financing that IKT received is officially confirmed, and the positive sentiment surrounding the company's recent developments is likely to sustain, providing a solid foundation for potential further increases in the stock price driven by investor confidence.